GB2526623A - New pharmaceutical use - Google Patents
New pharmaceutical use Download PDFInfo
- Publication number
- GB2526623A GB2526623A GB1409662.2A GB201409662A GB2526623A GB 2526623 A GB2526623 A GB 2526623A GB 201409662 A GB201409662 A GB 201409662A GB 2526623 A GB2526623 A GB 2526623A
- Authority
- GB
- United Kingdom
- Prior art keywords
- disease
- compound
- patient
- nbmi
- neurodegenerative disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 24
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 17
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 16
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 10
- QZUPTXGVPYNUIT-UHFFFAOYSA-N isophthalamide Chemical compound NC(=O)C1=CC=CC(C(N)=O)=C1 QZUPTXGVPYNUIT-UHFFFAOYSA-N 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- 208000024891 symptom Diseases 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 5
- 229960003638 dopamine Drugs 0.000 claims description 5
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 4
- 229960003805 amantadine Drugs 0.000 claims description 4
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 3
- 229960004181 riluzole Drugs 0.000 claims description 3
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 claims description 2
- YSGASDXSLKIKOD-UHFFFAOYSA-N 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 YSGASDXSLKIKOD-UHFFFAOYSA-N 0.000 claims description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 2
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 2
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims description 2
- 239000003954 decarboxylase inhibitor Substances 0.000 claims description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229960004502 levodopa Drugs 0.000 claims description 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims description 2
- 229950000659 remacemide Drugs 0.000 claims description 2
- 229960005333 tetrabenazine Drugs 0.000 claims description 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 1
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract description 10
- 229960003180 glutathione Drugs 0.000 abstract description 5
- 108010024636 Glutathione Proteins 0.000 abstract description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 abstract description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 3
- 235000018417 cysteine Nutrition 0.000 abstract description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 3
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 abstract description 2
- -1 co-enzyme A Chemical compound 0.000 abstract description 2
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 abstract description 2
- 229940099500 cystamine Drugs 0.000 abstract description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 abstract description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 abstract description 2
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 abstract description 2
- FFFHZYDWPBMWHY-UHFFFAOYSA-N L-Homocysteine Natural products OC(=O)C(N)CCS FFFHZYDWPBMWHY-UHFFFAOYSA-N 0.000 abstract 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 abstract 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical class OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 210000000274 microglia Anatomy 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 201000010099 disease Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 230000028327 secretion Effects 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 6
- 238000011533 pre-incubation Methods 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 4
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000003412 degenerative effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 208000005264 motor neuron disease Diseases 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000016273 neuron death Effects 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 230000009747 swallowing Effects 0.000 description 4
- 208000026072 Motor neurone disease Diseases 0.000 description 3
- 206010030312 On and off phenomenon Diseases 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 3
- 235000019136 lipoic acid Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960002663 thioctic acid Drugs 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010053317 Hexosaminidase A Proteins 0.000 description 2
- 102000016871 Hexosaminidase A Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 208000012601 choreatic disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 2
- 230000002025 microglial effect Effects 0.000 description 2
- 208000020337 multisystem proteinopathy Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002243 primary neuron Anatomy 0.000 description 2
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 229960004136 rivastigmine Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000002025 tabes dorsalis Diseases 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- GKJQHSSYBJHANH-UHFFFAOYSA-N 1,1-bis(sulfanyl)propane-1-sulfonic acid Chemical compound CCC(S)(S)S(O)(=O)=O GKJQHSSYBJHANH-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 201000006867 Charcot-Marie-Tooth disease type 4 Diseases 0.000 description 1
- 206010008589 Choking Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001905 GM2 Gangliosidoses Diseases 0.000 description 1
- 201000008905 GM2 gangliosidosis Diseases 0.000 description 1
- 208000009796 Gangliosidoses Diseases 0.000 description 1
- 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 description 1
- 102000016870 Hexosaminidase B Human genes 0.000 description 1
- 108010053345 Hexosaminidase B Proteins 0.000 description 1
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008498 Infantile Refsum disease Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 208000005716 Subacute Combined Degeneration Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 231100000076 Toxic encephalopathy Toxicity 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000005093 cerebellar hypoplasia Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002229 francium Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000006440 gangliosidosis Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000021995 hereditary motor and sensory neuropathy Diseases 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 208000028756 lack of coordination Diseases 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 201000005545 motor peripheral neuropathy Diseases 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000007431 neuroacanthocytosis Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- QULKGELYPOJSLP-WCABBAIRSA-N penicillin O Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CSCC=C)C(=O)N21 QULKGELYPOJSLP-WCABBAIRSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 208000020930 peroxisome biogenesis disorder 1B Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 208000004351 pontocerebellar hypoplasia Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 201000008752 progressive muscular atrophy Diseases 0.000 description 1
- 208000026526 progressive weakness Diseases 0.000 description 1
- 201000000196 pseudobulbar palsy Diseases 0.000 description 1
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229960003179 rotigotine Drugs 0.000 description 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960001032 trihexyphenidyl Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (30)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1409662.2A GB2526623A (en) | 2014-05-30 | 2014-05-30 | New pharmaceutical use |
| SI201531710T SI3148588T1 (sl) | 2014-05-30 | 2015-05-29 | N,N-bis-2-merkaptoetil izoftalamid za zdravljenje Parkinsonove bolezni |
| PT211808472T PT3903774T (pt) | 2014-05-30 | 2015-05-29 | N,n-bis-2-mercaptoetilisoftalamida para o tratamento de doenças neurodegenerativas |
| LTEP21180847.2T LT3903774T (lt) | 2014-05-30 | 2015-05-29 | N,n-bis-2-merkaptoetilizoftalamidas, skirtas neurodegeneracinių ligų gydymui |
| EP21180847.2A EP3903774B1 (en) | 2014-05-30 | 2015-05-29 | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases |
| PL15733860T PL3148588T3 (pl) | 2014-05-30 | 2015-05-29 | N,n-bis-2-merkaptoetyloizoftalamid do leczenia choroby parkinsona |
| LTEPPCT/GB2015/051572T LT3148588T (lt) | 2014-05-30 | 2015-05-29 | N,n-bis-2-merkaptoetilizoftalamidas, skirtas parkinsono ligos gydymui |
| HRP20230105TT HRP20230105T1 (hr) | 2014-05-30 | 2015-05-29 | N,n-bis-2-merkaptoetil izoftalamid za liječenje neurodegenerativnih bolesti |
| PT157338609T PT3148588T (pt) | 2014-05-30 | 2015-05-29 | N,n-bis-2-mercaptoetilisoftalamida para o tratamento de doença de parkinson |
| ES15733860T ES2882977T3 (es) | 2014-05-30 | 2015-05-29 | N,N-bis-2-mercaptoetil isoftalamida para el tratamiento de la enfermedad de Parkinson |
| RS20210852A RS62095B1 (sr) | 2014-05-30 | 2015-05-29 | N,n-bis-2-merkaptoetil izoftalamid za lečenje parkinsonove bolesti |
| FIEP21180847.2T FI3903774T3 (fi) | 2014-05-30 | 2015-05-29 | N,N-bis-2-merkaptoetyyli-isoftalamidi neurodegeneratiivisten sairauksien hoitoon |
| HUE15733860A HUE055575T2 (hu) | 2014-05-30 | 2015-05-29 | N,N-Bisz-2-merkaptoetil-izoftálamid Parkinson-kór kezelésére |
| PCT/GB2015/051572 WO2015181567A1 (en) | 2014-05-30 | 2015-05-29 | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases |
| ES21180847T ES2938080T3 (es) | 2014-05-30 | 2015-05-29 | N,N-bis-2-mercaptoetil isoftalamida para el tratamiento de enfermedades neurodegenerativas |
| RS20221189A RS63859B1 (sr) | 2014-05-30 | 2015-05-29 | N,n-bis-2-merkaptoetil izoftalamid za lečenje neurodegenerativnih bolesti |
| EP15733860.9A EP3148588B1 (en) | 2014-05-30 | 2015-05-29 | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease |
| US15/313,877 US20170202791A1 (en) | 2014-05-30 | 2015-05-29 | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases |
| HUE21180847A HUE060927T2 (hu) | 2014-05-30 | 2015-05-29 | N,N-bisz-2-merkaptoetil-izoftálamid neurodegeneratív betegségek kezelésére |
| DK15733860.9T DK3148588T3 (en) | 2014-05-30 | 2015-05-29 | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease |
| MA40065A MA40065B1 (fr) | 2014-05-30 | 2015-05-29 | N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson |
| PL21180847.2T PL3903774T3 (pl) | 2014-05-30 | 2015-05-29 | N,n-bis-2-merkaptoetyloizoftalamid do leczenia chorób neurodegeneracyjnych |
| SI201531911T SI3903774T1 (sl) | 2014-05-30 | 2015-05-29 | N,N-bis-2-merkaptoetil izoftalamid za zdravljenje nevrodegenerativnih bolezni |
| DK21180847.2T DK3903774T3 (da) | 2014-05-30 | 2015-05-29 | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases |
| US15/821,371 US20180250247A1 (en) | 2014-05-30 | 2017-11-22 | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases |
| MA54630A MA54630B1 (fr) | 2014-05-30 | 2020-02-06 | N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives |
| HRP20211309TT HRP20211309T1 (hr) | 2014-05-30 | 2021-08-13 | N,n-bis-2-merkaptoetil izoftalamid za liječenje parkinsonove bolesti |
| CY20211100788T CY1124509T1 (el) | 2014-05-30 | 2021-09-07 | Ν,ν-δις-2-μερκαπτοαιθυλο ισοφθαλαμιδιο για τη θεραπεια της νοσου toy parkinson |
| US17/558,975 US20220287994A1 (en) | 2014-05-30 | 2021-12-22 | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases |
| US17/953,622 US11628151B2 (en) | 2014-05-30 | 2022-09-27 | N,N-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1409662.2A GB2526623A (en) | 2014-05-30 | 2014-05-30 | New pharmaceutical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201409662D0 GB201409662D0 (en) | 2014-07-16 |
| GB2526623A true GB2526623A (en) | 2015-12-02 |
Family
ID=51214502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1409662.2A Withdrawn GB2526623A (en) | 2014-05-30 | 2014-05-30 | New pharmaceutical use |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20170202791A1 (hr) |
| EP (2) | EP3903774B1 (hr) |
| CY (1) | CY1124509T1 (hr) |
| DK (2) | DK3148588T3 (hr) |
| ES (2) | ES2938080T3 (hr) |
| FI (1) | FI3903774T3 (hr) |
| GB (1) | GB2526623A (hr) |
| HR (2) | HRP20230105T1 (hr) |
| HU (2) | HUE060927T2 (hr) |
| LT (2) | LT3148588T (hr) |
| MA (2) | MA40065B1 (hr) |
| PL (2) | PL3148588T3 (hr) |
| PT (2) | PT3903774T (hr) |
| RS (2) | RS62095B1 (hr) |
| SI (2) | SI3903774T1 (hr) |
| WO (1) | WO2015181567A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005057D0 (en) | 2020-04-06 | 2020-05-20 | Emeramed Ltd | New Use |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060099244A1 (en) * | 2004-11-07 | 2006-05-11 | Guilford F T | Liposomal formulation for oral administration of glutathione (reduced) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586600B2 (en) | 2000-12-06 | 2003-07-01 | University Of Kentucky Research Foundation | Multidentate sulfur-containing ligands |
| US8950583B2 (en) | 2008-12-06 | 2015-02-10 | Ermes Medical Company Limited | Method to remove heavy metals from a mammal |
| US8575218B2 (en) | 2009-09-28 | 2013-11-05 | The University Of Kentucky Research Foundation | Thiol-containing compounds for the removal of elements from tissues and formulations therefor |
| CA2775397A1 (en) | 2009-09-28 | 2011-03-31 | University Of Kentucky Research Foundation | Thiol-containing compounds for the removal of elements from contaminated milieu and methods of use |
| US20110237776A1 (en) | 2010-03-25 | 2011-09-29 | Haley Boyd E | Aromatic compounds with sulfur containing ligands |
| US8426368B2 (en) | 2010-03-25 | 2013-04-23 | The University Of Kentucky Research Foundation | Method of ameliorating oxidative stress and supplementing the diet |
-
2014
- 2014-05-30 GB GB1409662.2A patent/GB2526623A/en not_active Withdrawn
-
2015
- 2015-05-29 PT PT211808472T patent/PT3903774T/pt unknown
- 2015-05-29 PL PL15733860T patent/PL3148588T3/pl unknown
- 2015-05-29 DK DK15733860.9T patent/DK3148588T3/da active
- 2015-05-29 HR HRP20230105TT patent/HRP20230105T1/hr unknown
- 2015-05-29 ES ES21180847T patent/ES2938080T3/es active Active
- 2015-05-29 RS RS20210852A patent/RS62095B1/sr unknown
- 2015-05-29 RS RS20221189A patent/RS63859B1/sr unknown
- 2015-05-29 US US15/313,877 patent/US20170202791A1/en not_active Abandoned
- 2015-05-29 WO PCT/GB2015/051572 patent/WO2015181567A1/en active Application Filing
- 2015-05-29 MA MA40065A patent/MA40065B1/fr unknown
- 2015-05-29 FI FIEP21180847.2T patent/FI3903774T3/fi active
- 2015-05-29 PL PL21180847.2T patent/PL3903774T3/pl unknown
- 2015-05-29 HU HUE21180847A patent/HUE060927T2/hu unknown
- 2015-05-29 LT LTEPPCT/GB2015/051572T patent/LT3148588T/lt unknown
- 2015-05-29 PT PT157338609T patent/PT3148588T/pt unknown
- 2015-05-29 SI SI201531911T patent/SI3903774T1/sl unknown
- 2015-05-29 SI SI201531710T patent/SI3148588T1/sl unknown
- 2015-05-29 HU HUE15733860A patent/HUE055575T2/hu unknown
- 2015-05-29 EP EP21180847.2A patent/EP3903774B1/en active Active
- 2015-05-29 EP EP15733860.9A patent/EP3148588B1/en active Active
- 2015-05-29 DK DK21180847.2T patent/DK3903774T3/da active
- 2015-05-29 LT LTEP21180847.2T patent/LT3903774T/lt unknown
- 2015-05-29 ES ES15733860T patent/ES2882977T3/es active Active
-
2017
- 2017-11-22 US US15/821,371 patent/US20180250247A1/en not_active Abandoned
-
2020
- 2020-02-06 MA MA54630A patent/MA54630B1/fr unknown
-
2021
- 2021-08-13 HR HRP20211309TT patent/HRP20211309T1/hr unknown
- 2021-09-07 CY CY20211100788T patent/CY1124509T1/el unknown
- 2021-12-22 US US17/558,975 patent/US20220287994A1/en active Pending
-
2022
- 2022-09-27 US US17/953,622 patent/US11628151B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060099244A1 (en) * | 2004-11-07 | 2006-05-11 | Guilford F T | Liposomal formulation for oral administration of glutathione (reduced) |
Non-Patent Citations (3)
| Title |
|---|
| International Journal of General Medicine, vol. 4, 2011, pages 165-174 * |
| Neurochemistry International, vol. 36, 2000, pages 185-191 * |
| Oxidation and Biophysical Research Communications, vol. 334, 2005, pages 342-348 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10092564B2 (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| US20240041900A1 (en) | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | |
| CU23468B7 (es) | Forma de dosificación de pramipexol en una dosis única diaria | |
| Bellino et al. | Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study | |
| JP2007520488A (ja) | クエチアピン抗精神病薬による精神病の治療 | |
| AU2013357308B2 (en) | Compositions comprising vortioxetine and donepezil | |
| US20020048612A1 (en) | GABA substrate and the use thereof for treating cognitive and emotional disorders | |
| US11628151B2 (en) | N,N-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases | |
| US20120316247A1 (en) | Prevention and treatment of post-operative cognitive dysfunction (pocd) | |
| JPWO2008090736A1 (ja) | アルツハイマー型認知症の予防及び治療のための医薬 | |
| KR102254542B1 (ko) | 과다운동성 운동 장애의 예방 및/또는 치료에 사용하기 위한 치료제 | |
| NZ236055A (en) | Use of pyrimidine-substituted piperazine derivative in the treatment of depression | |
| US20050009813A1 (en) | Use of desoxypeganine for treating clinical depression | |
| EP3813816B1 (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome | |
| GB2524831A (en) | New pharmaceutical use | |
| TWI752282B (zh) | 苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途 | |
| KR20090031908A (ko) | Ｓｌｖ308 및 ｌ-ｄｏｐａ를 포함하는 병용 제제 | |
| US20130225671A1 (en) | Methods of Treating Seizure Disorders | |
| EP4262801A1 (en) | Masitinib for the treatment of alzheimer's disease | |
| Murphy | Treatment of Parkinsonism with laevodopa | |
| JP2018035076A (ja) | 網膜神経節細胞死抑制活性を有する経口用組成物 | |
| TW200815031A (en) | Combination preparations comprising bifeprunox and L-DOPA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| COOA | Change in applicant's name or ownership of the application |
Owner name: ERMES MEDICAL COMPANY LIMITED Free format text: FORMER OWNER: CTI SCIENCE LTD |
|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |